Overview
ONCY market data
Price History
ONCY price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.41 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.84 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,164.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.13 – $1.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $126M · P/B 17.13.
Company News
8-K filing — ONCOLYTICS BIOTECH INC (ONCY)SEC EDGAR · Jul 24, 2026, 8:40 PM
Oncolytics Biotech Receives FDA's Fast Track Designation To Pelareorep In Combination With A Checkpoint Inhibitor Treat Squamous Cell Carcinoma Of Anal CanalBenzinga · Jul 20, 2026, 1:01 PM
Oncolytics Biotech shares are trading higher after the company announced that it received FDA Fast Track Designation for pelareorep evaluation in certain forms of colorectal cancer.Benzinga · Jul 13, 2026, 3:03 PM
Oncolytics Biotech Receives FDA Fast Track Designation For Pelareorep Evaluation In Certain Forms Of Colorectal CancerBenzinga · Jul 13, 2026, 1:03 PM
Oncolytics Biotech Receives New U.S. Patent For Its Proprietary Manufacturing Process For PelareorepBenzinga · Jun 16, 2026, 1:10 PM
Oncolytics Biotech Promotes John McAdory To COOBenzinga · Jun 2, 2026, 1:05 PM
Oncolytics Biotech Announces Initial Data From Preclinical Study Supporting Further Evaluation Of Pelareorep In Combination With RAS Inhibitor Modalities In Solid Tumor ModelBenzinga · Jun 1, 2026, 1:08 PM
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $10 Price TargetBenzinga · May 26, 2026, 10:16 AM
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal TumorsGlobenewswire Inc · May 22, 2026, 1:15 PM
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesGlobenewswire Inc · May 14, 2026, 3:15 PM